Treatment of Branch Retinal Vein Occlusion induced Macular Edema with Bevacizumab by Abegg, Mathias et al.
BioMed  Central
Page 1 of 6
(page number not for citation purposes)
BMC Ophthalmology
Open Access Research article
Treatment of Branch Retinal Vein Occlusion induced Macular 
Edema with Bevacizumab
Mathias Abegg*, Christoph Tappeiner, Ute Wolf-Schnurrbusch, 
Daniel Barthelmes, Sebastian Wolf and Johannes Fleischhauer
Address: Department of Ophthalmology, Inselspital, University of Bern, Switzerland
Email: Mathias Abegg* - mhabegg@hispeed.ch; Christoph Tappeiner - tappeiner.c@gmx.net; Ute Wolf-Schnurrbusch - ute.wolf@insel.ch; 
Daniel Barthelmes - daniel.barthelmes@gmx.ch; Sebastian Wolf - sebastian.wolf@insel.ch; 
Johannes Fleischhauer - johannes.fleischhauer@insel.ch
* Corresponding author    
Abstract
Background: Branch retinal vein occlusion is a frequent cause of visual loss with currently
insufficient treatment options. We evaluate the effect of Bevacizumab (Avastin®) treatment in
patients with macular edema induced by branch retinal vein occlusion.
Methods: Retrospective analysis of 32 eyes in 32 patients with fluorescein angiography proven
branch retinal vein occlusion, macular edema and Bevacizumab treatment. Outcome measures
were best corrected visual acuity in logMAR and central retinal thickness in OCT.
Results: Visual acuity was significantly better 4 to 6 weeks after Bevacizumab treatment compared
to visual acuity prior to treatment (before 0.7 ± 0.3 and after 0.5 ± 0.3; mean ± standard deviation;
p < 0.01, paired t-test). Gain in visual acuity was accompanied by a significant decrease in retinal
thickness (454 ± 117 to 305 ± 129 μm, p < 0.01, paired t-test). Follow up (170, 27 – 418 days;
median, range) shows that improvement for both visual acuity and retinal thickness last for several
months after Bevacizumab use.
Conclusion:  We present evidence that intravitreal Bevacizumab is an effective and lasting
treatment for macular edema after branch retinal vein occlusion.
Background
Branch retinal vein occlusion (BRVO) is a frequent retinal
vascular disease with an incidence of 2.14/1000/year in
the population over 40 years of age[1]. It may cause
immediate vision loss due to reduced blood perfusion
and subsequent retinal hypoxia. It is also often is compli-
cated, with a temporal delay, by macular edema. The
edema may cause an additional reduction in visual acuity
that often exceeds the primary ischemic damage, and thus
represents an important treatment target. In the past mac-
ular edema was treated with focal photocoagulation and
more recently with intravitreal triamcinolone[2,3]. Both
treatments show a significant but limited success. It has
previously been shown that intravitreal levels of the vas-
cular endothelial derived growth factor protein (VEGF)
are significantly increased after BRVO[4] and it is cur-
rently thought that ischemia-induced upregulation of
VEGF causes a loosening of tight junctions which in return
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results in vascular leakage and edema. We therefore
sought to investigate the use of anti-VEGF therapy for
treatment of BRVO-induced macular edema.
Methods
Retrospective analysis was performed in 32 consecutive
eyes from 32 patients examined in our outpatient depart-
ment. 15 patients were female, 17 male. All patients had
fluorescein-angiography proven BRVO and at least one
injection of Bevacizumab (Avastin®). Patients were
included independently of a prior or concurrent treatment
with focal laser, intravitreal triamcinolone or hemodilu-
tion.
Examination of patients consisted of: (1) Determination
of best corrected visual acuity (BCVA) using Snellen
charts, (2) slit lamp examination, (3) measurement of
central retinal thickness (CRT) using the Zeiss® Stratus
OCT (Carl Zeiss Meditec AG, Oberkochen, Germany) and
(4) fluorescein angiography. BCVA was transformed into
logMAR values to facilitate statistical analysis. OCT
recordings were performed using the fast scan routine pro-
vided by the software. CRT (in μm) was measured in the
central circle provided by the 3 dimensional data analysis
tool.
Informed consent for off-label use of Bevacizumab was
obtained from all patients prior to injection. Bevacizumab
(1.25 mg) was injected intravitreally via pars plana under
sterile conditions in the operation theatre. Patients used
topical antibiotics (Tobramycin) 4 times per day for 1
week after the injection.
Primary outcome measures were changes in BCVA (in log-
MAR) and CRT compared to measures made at indication
of treatment (referred to as 'before'). All values in this arti-
cle are expressed as median and range or as mean ± stand-
ard deviation respectively, where indicated. For statistical
analysis student's paired t-test was used. Spearman's rank
correlation coefficient was applied for correlation analy-
sis. A p-value of < 0.01 was considered as statistically sig-
nificant.
Our study complied with the provisions of the Declara-
tion of Helsinki and was approved by the local ethics
committee.
Results
Baseline Characteristics
Median age of patients was 65 years, ranging from 48 to
87 years. BCVA at the time of diagnosis was 0.46 ± 0.3 log-
MAR. CRT was 437 ± 164 μm. Time between diagnosis
and the first Bevacizumab injection ranged from 5 days to
18 years, median was 113 days. Median time interval
between indication of treatment and the actual injection
was 9 days, ranging from injection on the same day to 44
days later. 47% of all patients had focal laser photocoagu-
lation, 13% intravitreal triamcinolone treatment and 6%
had prior hemodilution. Additional treatments are listed
in Table 1. No laser, triamcinolone or hemodilution was
applied between the last consultation before and the first
consultation after Bevacizumab treatment.
Short-term effects of Bevacizumab
Within 6 weeks after injection BCVA and CRT were deter-
mined. The mean follow up interval was 30 ± 11 days.
BCVA was 0.68 ± 0.3 and 0.5 ± 0.35 logMAR, before and
after injection respectively (p < 0.01, paired t-test). CRT
decreased from 454 ± 117 μm to 305 ± 129 μm (p < 0.01,
paired t-test). 41% of all injected eyes showed a visual
improvement of at least 2 lines after injection. BCVA
remained unchanged in 53% and decreased by ≥ 2 lines in
6%. An example of a patient with favorable outcome is
shown in figure 1. To investigate whether the temporal
delay from diagnosis until treatment initiation altered the
outcome, we correlated the time span from diagnosis of
BRVO until the first injection of Bevacizumab with the vis-
ual gain, i.e. improvement of visual acuity 4 to 6 weeks
after the first injection. There was no significant correla-
tion found (Rho = 0.01, p = 0.9, Spearman's Rho Test, fig-
ure 2). Thus, in our group of patients the duration of
presence of the BRVO seems not to influence visual gain
induced by Bevacizumab treatment.
Long-term effects of Bevacizumab
Repeated injections were performed if macular edema
recurred after an initial decrease. 53% of all patients had
only one injection at the time of analysis, 28% had two
and 18% more than two. A mean of 1.7 injections were
made per patient with an interval between injections of 92
days, range 42 – 306 days. Treatment was stalled when
vision and CRT reached steady state, i.e. did not deterio-
rate more than one line (corresponding to maximally 0.3
logMAR units) and/or retina did not thicken more than
10% compared to the measures obtained six weeks after
the last Bevacizumab injection.
Follow-up data ranging from 27 – 418 days, median 170
days were evaluated. For each patient a timeline was cal-
culated. Timelines were aligned for all patients with day 0
defined as time of first Bevacizumab injection. Data was
binned with monthly intervals in order to obtain graphs
as shown in figure 3. One month prior to first injection,
visual acuity was better than at the time the decision for
treatment with Bevacizumab was made. Bevacizumab led
to a rapid improvement of visual acuity that was lasting
for several months. This was paralleled by a similar time
course for OCT measures, which showed increased CRT at
day 0 and a lasting decrease thereafter.BMC Ophthalmology 2008, 8:18 http://www.biomedcentral.com/1471-2415/8/18
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Discussion and conclusion
We show that intravitreal Bevacizumab treatment for mac-
ular edema induced by BRVO leads to a fast and signifi-
cant improvement of visual acuity and a concurrent
decrease of CRT. Similar results were previously accom-
plished with intravitreal administration of triamci-
nolone[3]. In contrast to triamcinolone however we did
not observe any of the severe and rather frequent ocular
side effects of intravitreal triamcinolone administration
such as rise in intraocular pressure or cataract formation.
Our preliminary data on longer term effects suggest that
the rapid beneficial effects of Bevacizumab last for several
months, although individual patients require repeated
injections. A natural course of the disease could not be
predicted since the retrospective study design did not
include a control group.
Our findings are in agreement with published case series
showing that Bevacizumab treatment leads to improved
visual function and decreased CRT in patients suffering
from BRVO with macular edema [5-11]. These studies
show a beneficial effect of Bevacizumab on both visual
acuity and CRT. However, they reveal a great variability in
injection frequencies, follow up time and treatment inter-
val. Whereas Pai et al.[6], Stahl et al.[8] and Jaissle et al.[5]
Table 1: Additional treatments
Patient Time-to-Treat 
[d]
Visual Gain Follow-up [d] Total Injections Focal Laser [m] Hemodilution Intravitreal 
Triamcinolone 
[m]
Other
1 2232 0.0 119 1 - - - -
2 59 0.8 57 1 - - - -
31 9 0 . 2 3 4 1 4 - y - -
47 7 0 . 2 1 7 2 2 - - - -
5 6715 0.3 94 1 -1 - - -
6 17 1.1 221 3 +4,+13 - - -
73 7 0 . 7 2 5 0 3 - - - -
8 211 0.2 109 1 - - - -
96 0 . 0 9 1 1 - - - -
10 1041 0.1 193 2 - - - -
11 26 -0.1 33 1 - - - -
12 505 0.0 90 1 -14,-12,-9,-8,-3,-
2
- -14, +2 -
13 9 0.0 278 2 +1,+2,+8,+12 - +9 -
14 456 0.6 236 2 +1,+2,+3,+7 - -15 -
15 973 0.1 57 1 -27,-24 - - -
16 598 0.2 27 1 -8,-3 - -3 -
17 134 0.3 418 1 -3,-2,+13 - - -
18 10 0.6 179 2 - - - -
19 216 0.1 339 2 +1 - - -
20 5 -0.2 171 2 +1,+4,+6 - - -
21 1794 0.3 284 4 +1 - - -
22 5 0.3 38 1 - - - -
23 64 0.2 48 1 - y - -
24 254 0.1 234 4 +2,+7 - - -
25 626 0.1 31 1 - - - -
26 5 -0.2 168 2 - - - -
27 47 0.6 229 3 +6,+7,+11 - - -
28 92 -0.3 28 1 -3 - - -
29 854 0.0 81 1 - - - vitrectomy at +2 
m for tractive 
retinal 
detachment
30 312 0.1 360 2 -2,+7 - - vitrectomy at +7 
m for vitreous 
hemorrhage
31 8 0.1 96 1 - - - -
32 371 0.0 175 1 - - - -
Patients were treated prior and/or after initiation of Bevacizumab treatment with focal laser or intravitreal triamcinolone. Hemodilution was made 
within the first weeks of diagnosis. No additional treatment was applied between the first injection and the subsequent visit 4 to 6 weeks later. 
Time points are represented in months (m) or days (d) prior to (negative values) or after (positive values) the first Bevacizumab injection.BMC Ophthalmology 2008, 8:18 http://www.biomedcentral.com/1471-2415/8/18
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show only small case series, a study by Rabena et al.[7]
with 27 patients is comparable to our study. Rabena et
al.[7] had more dry patients after a single injection (80%),
whereas in our hands 45% of the patients required more
than one application of Bevacizumab. Three larger series
published in 2008 come to similar conclusions: both pro-
spective[9,10] and retrospective[11] analysis demonstrate
that repeated applications of Bevacizumab are necessary
for long lasting results on visual acuity and CRT.
Anti-VEGF treatment is not limited to either Bevacizumab
or BRVO: Campochiaro et al. demonstrated that Ranibizu-
mab, similar to Bevacizumab, leads to improved visual
acuity and CRT in BRVO[12]. In addition to treating
BRVO, Bevacizumab was used for central retinal vein
occlusion: visual acuity, retinal thickness(see for example
[13]) and ERG amplitudes[14] improved after Bevacizu-
mab treatment in patients with macular edema due to
central retinal vein occlusion.
Despite an increasing body of evidence for the efficacy of
anti-VEGF treatment for macular edema associated with
vein occlusion, an optimal treatment regime is yet to be
determined. Indication for treatment and retreatment is
based on deterioration of BCVA and retinal thickness,
whereas an optimal treatment plan would act prophylac-
tically. In our series, visual acuity was determined about 1
week prior to actual intravitreal injection. If we assume
that visual deterioration continued during this interval,
then our data represents rather an underestimate of the
real efficacy of Bevacizumab.
Even though an optimal treatment regimen is as yet
unclear, our data suggests that treatment should be initi-
ated even if BRVO has been present for a while: in our
patients the temporal delay from diagnosis to treatment
initiation did not influence visual outcome (figure 2).
This might be explained by the fact that the indication for
treatment was based on the development of macular
edema, which itself evolves with a temporal delay. Our
dataset however did not allow a clarification of this issue.
Similar observations were made in recently published
series [9-11].
Example of a patient treated with Bevacizumab for branch retinal vein occlusion (BRVO) associated macular edema Figure 1
Example of a patient treated with Bevacizumab for branch retinal vein occlusion (BRVO) associated macular 
edema. Left, fundus photograph and fluorescein angiography show a non ischemic macular BRVO with macular edema in the 
left eye. Right, follow up of visual acuity and OCT for the same patient. As the edema increased and visual acuity worsened 
Bevacizumab treatment was indicated (day-9) and performed (day 0). Time course shows rapid improvement of visual acuity 
and macular edema, which was followed twice by a recurrence requiring further Bevacizumab injections (marked with Inj).BMC Ophthalmology 2008, 8:18 http://www.biomedcentral.com/1471-2415/8/18
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Short term effects of Bevacizumab on visual acuity and retinal thickness Figure 2
Short term effects of Bevacizumab on visual acuity and retinal thickness. Top left panel, box plot of logMAR visual 
acuity significantly improves 4 to 6 weeks after Bevacizumab injection. Boxes indicate 25 and 75 percentile, whiskers indicate 
10 and 90 percentile, line within the box marks the median. Visual acuity and retinal thickness at the time the indication for 
treatment was made (before) is compared to measures taken within 6 weeks after injection (after). Top right panel, raw data 
for individual patients show that some patients respond with improved visual acuity whereas others fail to improve. Bottom 
left, box plot shows significant decrease of CRT after Bevacizumab application. Bottom right, correlation of visual gain and tem-
poral delay from diagnosis of BRVO until first Bevacizumab treatment shows that improvement of visual acuity occurs inde-
pendently of the age of BRVO. Note that time axis is logarithmic.
Follow up of visual acuity and central retinal thickness Figure 3
Follow up of visual acuity and central retinal thickness. Binned and temporally aligned data shows that Bevacizumab 
injection is preceded by a recent worsening of both visual acuity and CRT. Treatment results in a rapid and lasting improve-
ment for both, requiring several injections though. Bin size is shown within bars; whiskers on bars represent standard devia-
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In conclusion our results suggest anti-VEGF treatment is a
valuable therapy for BRVO-associated macular edema.
Randomized clinical trials are now required for further
evaluation.
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